Neurogene
NGNE
39 hedge funds and large institutions have $10.5M invested in Neurogene in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 15 reducing their positions, and 11 closing their positions.
22% more capital invested
Capital invested by funds: $8.66M → $10.5M (+$1.88M)
0.24% less ownership
Funds ownership: 2% → 1.76% (-0.24%)
13% less funds holding
Funds holding: 45 → 39 (-6)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
73% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$152K |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$80.4K |
| 3 |
MA
MYDA Advisors
Woodmere,
New York
|
+$23.4K |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$13.9K |
| 5 |
US Bancorp
Minneapolis,
Minnesota
|
+$13.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$475K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$274K |
| 3 |
Barclays
London,
United Kingdom
|
-$262K |
| 4 |
Renaissance Technologies
New York
|
-$163K |
| 5 |
JP Morgan Chase
New York
|
-$42.6K |
NGNE Hedge Fund Activity: Q1 2023 in Review
39 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q1 2023, worth a combined $10.5M — up 22% from $8.66M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of NGNE and 5 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 4 added.
The largest buyer was Morgan Stanley, adding an estimated $152K. The largest seller was Millennium Management, cutting an estimated $475K.
- 39 institutional investors held Neurogene (NGNE) as of Q1 2023, down from 45 in Q4 2022.
- Funds reported $10.5M of Neurogene stock for Q1 2023, up 22% quarter-over-quarter.
- 5 funds opened new Neurogene positions in Q1 2023 and 11 closed out, a net change of -6 holders.
- The largest Neurogene buyer in Q1 2023 was Morgan Stanley, an estimated $152K added.
- The largest Neurogene seller in Q1 2023 was Millennium Management, an estimated $475K sold.
Based on aggregated 13F filings for Q1 2023.